Scott Summers

Has grant

Co-Director

University of Utah
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Targeting a Ceramide Double Bond to Treat Cardiometabolic Disorders

Open Date: 2019-07-15

Close Date: 2023-04-30

Grant: Close

FASEB SRC on Regulation of Glucose Metabolism: From Cell Biology to Systems Physiology

Open Date: 2019-06-01

Close Date: 2020-05-31

Grant: Close

The Role of Ceramides in Skeletal Muscle

Open Date: 2018-01-01

Close Date: 2021-12-31

Grant: Close

Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases

Open Date: 2017-09-15

Close Date: 2020-08-31

Grant: Close

Lipid Mediators of Insulin Resistance

Open Date: 2008-07-01

Close Date: 2013-10-30

Articles (25)

Year:

2026

Year:

2026

Metabolic-associated steatohepatitis (MASH) involves hepatocyte damage that cannot be explained solely by lipid accumulation. Here, to discover injury-specific pathways, we focused on a gene of uncertain function, EF-Hand Domain Family Member D1 (EFHD1), identified in human genome-wide association studies of liver injury but not liver fat. We show that EFHD1, a Ca 2+ -dependent actin crosslinker, stabilizes endoplasmic reticulum–mitochondria contact sites (ERMCS), detecting spatiotemporal coincidence of inter-organellar proximity and ER Ca 2+ release. During MASH, EFHD1 upregulation drives pathological mitochondrial fragmentation via excessive contact persistence. This structural failure promotes mitochondrial double-stranded RNA escape and activation of a maladaptive antiviral PKR-dependent stress response, a causal relationship also supported by Mendelian randomization in humans. Consequently, inhibiting EFHD1 in human and mouse models blunts hepatocyte damage. These findings identify EFHD1 as a Ca 2+ -dependent ERMCS stabilizer, reveal a hepatocyte-intrinsic injury pathway, and suggest EFHD1 inhibition as a therapeutic strategy.

Year:

2026

Gestational diabetes mellitus (GDM), a transient form of diabetes that resolves postpartum, is a major risk factor for type 2 diabetes (T2D) in women. While the progression from GDM to T2D is not fully understood, it involves both genetic and environmental components. By integrating clinical, metabolomic, and genome-wide association study (GWAS) data, we identified associations between decreased sphingolipid biosynthesis and future T2D, in part through the rs267738 allele of the CERS2 gene in Hispanic women shortly after a GDM pregnancy. To understand the impact of the CERS2 gene and risk allele on glucose regulation, we examined whole-body Cers2 knockout and rs267738 knock-in mice. Both models exhibited glucose intolerance and impaired insulin secretion in vivo. Islets isolated from these models also demonstrated reduced β cell function, as shown by decreased insulin secretion ex vivo. Overall, reduced circulating sphingolipids may indicate a high risk of GDM-to-T2D progression and reflect deficits in CERS2 activity that negatively affect glucose homeostasis and β cell function.

Year:

2025

Obesity is a global menace that has impacted more than 14% of adults worldwide and more than a third of Americans. Importantly, obesity is associated with an increased risk of more than 13 types of cancer and worse outcomes, including increased mortality. This review focuses on the importance of considering obesity and metabolic dysfunction in cancer risk as part of the NCI’s funded consortium known as the Metabolic Dysfunction and Cancer Risk Program. It describes previous and ongoing mouse models used in studies conducted by Metabolic Dysfunction and Cancer Risk Program consortium members, as well as other relevant studies. Most cancer studies examine tumor progression, metastasis, or recurrence, which are consequences following tumor onset; however, this approach does not consider risk per se. To truly model cancer risk, parameters to measure include the quantification of cancer onset, measured as incidence or latency. Investigators must be cognizant of many factors in study design, including the choice of cancer model and genetic strain. Preclinical approaches addressing risk typically include genetically engineered mouse models or the administration of irritants or carcinogens. We also discuss the transplantation of cells or tumors such as allografts or xenografts, with a focus on tumor rejection or regression to approximate cancer risk, not cancer progression. Herein, we highlight two cancers, breast and colorectal cancers, in which risk is associated with obesity and discussed varied murine model approaches, as well as key findings that explore cancer risk, prevention, or interception.

Year:

2025

Supplemental Table 3 provides effect estimates for the association of incident diabetes and all-cause mortality among obesity-related cancer survivors and cancer-free individuals, stratified by covariates that did not meet PH assumptions.

Year:

2025

Supplemental Table 6 provides effect estimates for the association of incident diabetes and cancer-specific mortality among obesity-related cancer survivors, stratified my covariates that did not meet PH assumptions.

Year:

2025

Supplemental Table 1. Criteria for metabolic phenotype classification. HDL high density lipoprotein cholesterol; HOMA-IR Homeostatic Model Assessment for Insulin Resistance ; hs-CRP high sensitive C-reactive protein

Year:

2025

Supplemental Figure 7. Hazard ratios and 95% confidence intervals for the association of metabolic phenotype defined by Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) with obesity-related cancer risk, stratified by cancer type among postmenopausal women in the Women’s Health Initiative. Model adjusted for demographics (age, education, race/ethnicity, marital status), lifestyle (smoking status, physical activity, alcohol use, fruits and vegetable intake, fiber intake, read meat intake), hormonal factors for female cancers (parity, hormone therapy use), family history of ORC and study ID. MUNW=metabolically unhealthy normal weight; MHO=metabolically healthy overweight/obese; MUO= metabolically unhealthy overweight/obese. Metabolically healthy normal weight (MHNW) is the comparison group.

Year:

2025

Supplemental Figure 5. Hazard ratios and 95% confidence intervals for the association of metabolic phenotype defined by ATP III criteria with obesity-related cancer risk, stratified by cancer type among postmenopausal women in the Women’s Health Initiative. Model adjusted for demographics (age, education, race/ethnicity, marital status), lifestyle (smoking status, physical activity, alcohol use, fruits and vegetable intake, fiber intake, read meat intake), hormonal factors for female cancers (parity, hormone therapy use), family history of ORC and study ID. MUNW=metabolically unhealthy normal weight; MHO=metabolically healthy overweight/obese; MUO= metabolically unhealthy overweight/obese. Metabolically healthy normal weight (MHNW) is the comparison group.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (36)

Shama Karanth

Assistant Professor

University of Florida

UNITED STATES
View details

Marc Gunter

International Agency for Research on Cancer

FRANCE
View details

Md Saifur Rahman Khan

Director, Bioinformatics and Metabolomics Unit, The Center for Immunometabolism

University of Pittsburgh

UNITED STATES
View details

Garnet Anderson

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Babak Razani

Chief of Cardiology

VA Pittsburgh Healthcare System

UNITED STATES
View details

Sihem Boudina

University of Utah

UNITED STATES
View details

Aladdin Shadyab

Associate Professor

University of California, San Diego

UNITED STATES
View details

Vivek Garg

Assistant Professor

University of Maryland

UNITED STATES
View details

Fred Tabung

University of South Carolina

UNITED STATES
View details

Julie Van

University of Toronto

CANADA
View details

Marian Neuhouser

Professor

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Enrique Balderas-Angeles

University of Utah

UNITED STATES
View details

Mary Playdon

Assistant Professor

University of Utah

UNITED STATES
View details

Md Monowarul Mobin Siddique

Assistant Professor

University of Utah

UNITED STATES
View details

Bing Li

Professor

The University of Iowa

UNITED STATES
View details

Rebecca Seguin-Fowler

Associate Professor

Texas A&M University

UNITED STATES
View details

Jared Rutter

Professor

University of Utah

UNITED STATES
View details

Sheetal Hardikar

University of Utah

UNITED STATES
View details

Liza Makowski

Professor

University of Tennessee Health Science Center

UNITED STATES
View details

Dipayan Chaudhuri

University of Utah

UNITED STATES
View details

Cynthia A. Thomson

-

UNITED STATES
View details

Jean Wactawki-Wende

Dean, Suny Distinguished Professor

University at Buffalo

UNITED STATES
View details

Xiaochen Zhang

Assistant Professor

Ohio State University

UNITED STATES
View details

Katherine Cook

Associate Professor

Wake Forest University

UNITED STATES
View details

Su Yon Jung

University of California, Los Angeles

UNITED STATES
View details

William L. Holland

Associate Professor

University of Utah

UNITED STATES
View details

juhua luo

Professor

Indiana University Bloomington School of Public Health

UNITED STATES
View details

Kimberley Evason

Associate Professor

University of Utah

UNITED STATES
View details

Michael B Wheeler

Professor

University of Toronto

CANADA
View details

E. Angela Murphy

Professor

Medical University of South Carolina

UNITED STATES
View details

Patrice N Mimche

Associate Professor

Indiana University School of Medicine

UNITED STATES
View details

Robin Shaw

Director

University of Utah

UNITED STATES
View details

Yangbo Sun

Assistant Professor

University of Tennessee Health Science Center

UNITED STATES
View details

marcia stefanick

Stanford University

UNITED STATES
View details

Ting-Yuan Cheng

Associate Professor

Ohio State University

UNITED STATES
View details

Nazmus Saquib

-

SAUDI ARABIA
View details